1. Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma
   Mitra Korani et al, 2019, Nanomedicine: Nanotechnology, Biology and Medicine CrossRef
2. Nanomaterials in Cancer Therapy
   Jayasree S. Kanathasan et al, 2023, Cutting-Edge Applications of Nanomaterials in Biomedical Sciences CrossRef
3. Micro and nanotechnologies: The little formulations that could
   Rebeca T. Stiepel et al, 2023, Bioengineering & Translational Medicine CrossRef
4. Nanomedicine-based commercial formulations: current developments and future prospects
   Raj Kumar Thapa et al, 2023, Journal of Pharmaceutical Investigation CrossRef
5. Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use
   Mia Baxter-Holland et al, 2018, Journal of Pharmacy and Pharmacology CrossRef
6. Dalbergioidin Ameliorates Doxorubicin-Induced Renal Fibrosis by Suppressing the TGF-βSignal Pathway
   Xianguo Ren et al, 2016, Mediators of Inflammation CrossRef
7. A Nanomedicine Structure–Activity Framework for Research, Development, and Regulation of Future Cancer Therapies
   Brian Youden et al, 2022, ACS Nano CrossRef
8. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial
   Clémence Romeo et al, 2019, Gynecologic Oncology CrossRef
9. Amaranthus spinosus (Spiny Pigweed) methanol leaf extract alleviates oxidative and inflammation induced by doxorubicin in male sprague dawley rats
   O. A. Akinloye et al, 2023, Advances in Traditional Medicine CrossRef
10. Prognostic and predictive roles of microRNA‑411 and its target STK17A in evaluating radiotherapy efficacy and their effects on cell migration and invasion via the p53 signaling pathway in cervical cancer
    Wei Wei et al, 2019, Molecular Medicine Reports CrossRef
11. Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
    Akiho Fukuda et al, 2017, PLOS ONE CrossRef
12. Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
    Kenan Aloss et al, 2023, Pharmaceutics CrossRef
13. Replacing cholesterol with asiatic acid to prolong circulation and enhance anti-metastatic effects of non-PEGylated liposomes
    Yicong Zhang et al, 2024, Journal of Controlled Release CrossRef